EBOLA VACCINE SHOWS IMMUNE RESPONSE IN 60 VOLUNTEERS

摘要

An Ebola vaccine being developed by GlaxoSmithKline and the US National Institutes of Health is well tolerated and generates an immune response, according to initial testing of the vaccine in 60 healthy volunteers. The vaccine candidate, known as 'ChAd3', uses a single Ebola virus gene delivered by a chimpanzee adenovirus-3 vector. It is designed to target the Zaire strain of Ebola, which is responsible for the current outbreak in West Africa that has caused more than 8,500 deaths.